Erik Harris

October 16, 2026

RARE FDA approves Fayuvi, triggers $203M voucher sale. Ultragenyx Pharmaceutical received FDA approval for its gene therapy Fayuvi. The approval was followed by a second sale of a priority review voucher, bringing in about $203 million within a week. The cash from the voucher sale adds to the company’s resources as it looks to expand its approved product portfolio. Analysts are evaluating whether the newly approved product can support the next growth phase.

September 25, 2026

Rezolute Q4 EPS Misses Estimates, Reports Fiscal 2026 Results. Rezolute reported fourth-quarter and full-year fiscal 2026 financial results, with an EPS of $(0.20) missing the expected $(0.15). The company also provided a business update alongside these figures. The stock is currently trading near its support level, reflecting the market's reaction to the earnings miss.

October 9, 2026

Denali Therapeutics Shares Test Fair Value Amid Pullback. Denali Therapeutics shares have pulled back, testing the $19.37 support level. The 14‑day RSI sits at 30, indicating a possible oversold condition, while the support_reject signal suggests the level may hold. Analysts average a target of $36.06, with a range of $27 to $42, well above the current price and the 52‑week low of $13.75. The pullback could be seen as a chance to assess fair value.